Dr. Robert T. Lum

technology," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development."This library of computational molecular

Robert T. Lum, Ph.D., Vice President, Preclinical Development, Telik.

Product Details and Availability

Robert T. Lum, Ph.D.
...
Robert T. Lum, Ph.D., has served as the Company's Vice President, Preclinical Development since January 2002 and as Director, Medicinal Chemistry since January 2000.Dr. Lum joined the Company in February 1998 as Associate Director, Medicinal Chemistry.Prior to joining the Company, Dr. Lum served as Assistant Director, Medicinal Chemistry, at CV Therapeutics, Inc. from January 1994 to January 1998.Prior to 1994, he was a Scientist at Arris Pharmaceutical Corporation and an Associate Senior Investigator at Smithkline Beecham Corporation.Dr. Lum has authored numerous scientific publications and patents.Dr. Lum holds a Ph.D. degree in chemistry from the Massachusetts Institute of Technology and a B.S. degree from the University of California at Berkeley.

"This milestone is the latest achievement as we advance Telik's TRAP technology," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development.

IBM's System Cluster 1350 has allowed us to complete calculations 50 times faster than our previous solutions, and since our compute jobs can run for several months, the Linux operating system offers reliability that is critical in our drug development," said Robert T. Lum, Ph.D., Vice President, Preclinical Development, Telik.

President - Robert Lum, MD

"Dr. Aaronson, an internationally recognized expert in cancer biology, has developed novel assays for leading edge cancer targets that can be used to identify pharmaceutically active compounds," said Robert Lum Ph.D., vice president of preclinical development.

Robert T. Lum, Ph.D.Vice President, Preclinical Development
...
Robert T. Lum, Ph.D.Vice President, Preclinical Development

Dr. Lum has served as our Vice President, Preclinical Development since January 2002 and has been with Telik since 1998.Prior to joining us, he was at CV Therapeutics, Inc., Arris Pharmaceutical Corporation and SmithKline Beecham Corporation.The author of numerous scientific publications and patents, Dr. Lum holds a B.S. degree from the University of California, Berkeley and a Ph.D. degree in chemistry from the Massachusetts Institute of Technology.

"TRAP is well-suited for post-genomic cancer drug discovery since it provides an efficient and rapid means of identifying active compounds across a wide diversity of targets," said Robert T. Lum, Ph.D., Vice President, Preclinical Development."It is also a means for accelerating the translation of basic cancer research results to clinical applications."

On Tuesday, April 9 from 1:00 p.m. to 5:00 p.m., Telik scientists will present "TLK286-Induced Activation of the Stress Response Apoptotic Signaling Pathway" (Abstract # 4772, poster session New Targets - New Agents 2).TLK286 is in Phase 2 testing in colorectal, ovarian, non-small cell lung and breast cancer.TLK 286 is activated by glutathione S-transferase (GST) P1-1, an enzyme which is over-expressed in many types of human cancers.Elevated GST P1-1 levels also are correlated with the development of resistance to many commonly used chemotherapeutic drugs.